Mutant RAS is associated with an earlier and higher rate of local tumour progression in patients undergoing ablation of CLMs.
No takes yet. Share an insight, caveat, or question.
Odisio et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: